Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 90 Publications

16 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).



    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.



    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.



    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.



    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.



    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • 3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.



    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

  • MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h



    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.



    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  M3;pR2NmdGxiVnnhZoltcXS7IFHzd4F6 MmTsNlUxKG6PwrC= MnPLO|IhcA>? NGD4[3BFVVOR NY\iOHpz[2G3c3XkJFk4LSCub4PzJI9nKH[rYXLpcIl1gSCrbjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKEKFTE[gd4lTVkF? MXyyOlY2PzJ6OB?=
KG1a MljnR4VtdCCYaXHibYxqfHliQYPzZZk> NH7t[3YxNTFyIN88US=> M3XyO|I1KGh? NGm1SmRFVVOR MmHFTWM2OD15Lk[4JO69VSxiZHXjdoVie2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH3XRZAzPjV3MkexNi=>
Kasumi-1 NYmzfpJGS2WubDDWbYFjcWyrdImgRZN{[Xl? NHGySoUxNTFyIN88US=> NX:ycI5oOjRiaB?= MXLEUXNQ NIDlXnRKSzVyPUSuPFch|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGXOe5EzPjV3MkexNi=>
KG1a M1\GVmFxd3C2b4Ppd{BCe3OjeR?= NEjBO4sxNTFyIN88US=> NEPhZ3ozPCCq MV7EUXNQ MlLKbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3XvV|I3PTV{N{Gy
Kasumi-1 MlfwRZBweHSxc3nzJGF{e2G7 NWPkeYV2OC1zMDFOwG0> MXOyOEBp MonUSG1UVw>? NYnEO|JPcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHi3fI4zPjV3MkexNi=>
MC-3  NFXHNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG1M|ExNzJyIN88US=> MWCyOEBp MWXEUXNQ MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M37VO|I3PDR5NkG1
HN22  NXvGXmQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HWS|IvPS95LkWvNlIvPSEQvF2= NWDYXWFjOjRiaB?= MoXwSG1UVw>? M3HGcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2LHSVI3PDR5NkG1
HN22  M4P2TmFxd3C2b4Ppd{BCe3OjeR?= NE\HUYgzNjVxNz61M|IzNjVizszN M{HJWFI1KGh? M{LPWmROW09? NGexc4NqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz MVOyOlQ1PzZzNR?=
MOLT-4 NInpVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPXTJYyOC13MECwJI5O MmrRO|IhcA>? NYHteJQ6TE2VTx?= MYfJR|UxRTBwMUm4JO69VQ>? M1PtU|I3Ozl{M{Oy
RS4;11 NETNSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L5VVExNTVyMECgcm0> NHzrboI4OiCq MYjEUXNQ NYrofVRoUUN3ME2wMlAxOiEQvF2= MX[yOlM6OjN|Mh?=
JURKAT M{\W[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqxNE02ODByIH7N NIL5VZE4OiCq NX[ze|AzTE2VTx?= NYfNNWc6UUN3ME22OkDPxE1? MlT1NlY{QTJ|M{K=
CEM R MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP1NVAuPTByMDDuUS=> MomxO|IhcA>? MVfEUXNQ MnvLTWM2OD13LkSg{txO NFn1TlgzPjN7MkOzNi=>
MOLT-4 MYXBdI9xfG:|aYOgRZN{[Xl? M3;ITVExNTFyMECgcm0> MWKyOEBp NWPKU2NVTE2VTx?= M1v5TINifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x NUPD[YtLOjZ|OUKzN|I>
CEM S MULBdI9xfG:|aYOgRZN{[Xl? NXXPVolzOTBvMUCwNEBvVQ>? Ml25NlQhcA>? NWrXe2s2TE2VTx?= NUPNfWRJ[2G3c3XzJJRp\SClbHXheoFo\SCxZjDCZ4wuOiCjbnSgeIhmKGSxd37y[Yd2dGG2aX;uJI9nKEKlbD34UEBidmRiTXPsMVE> NEPVRVMzPjN7MkOzNi=>
JURKAT NXzE[nF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6xNFAuOTByMDDuUS=> NV;IOJlmPDhiaB?= M3\VemROW09? M1\PWmlEPTB;OUW1xtE6NjNibl2= MW[yOlE4OjJ4OR?=
LOUCY M1nEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;keJUyODBvMUCwNEBvVQ>? NEPCOYg1QCCq Mo\NSG1UVw>? NHfPW4VKSzVyPUOyMljDuTFyLkmgcm0> MmiwNlYyPzJ{Nkm=
WM-115 Ml;IR4VtdCCYaXHibYxqfHliQYPzZZk> MmPjNVAxyqCwTR?= M1\IPVczKGh? M1\seIVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi NIH2d2MzPjFzNke3Oi=>
B16 NETxO3dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX2xNFDDqG6P NWL2N2M5PzJiaB?= Mn\s[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB? M1vaflI3OTF4N{e2
HL-60  NVv6SFZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\YZ|BWPzJiaB?= MXzJR|UxyqB;IEGwMlchdk1? NXHHPYxxOjZyNEW2NFk>
MOLM-13  NEGwbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi2UIc4OiCq MULJR|UxyqB;IEK3Mlkhdk1? MUWyOlA1PTZyOR?=
OCI-AML3 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[5e284OiCq M3nIc2lEPTEEoE2gNVk2OCCwTR?= MYCyOlA1PTZyOR?=
BCWM.1 NFPrXmtCeG:ydH;zbZMhSXO|YYm= NXPrSVQxOC1zLk[g{txO M{\kVVI1KGh? NFf4PW9qdmS3Y3XzJINmdGxiYYDvdJRwe2m| NF:2b4gzPTh7M{K5NC=>
MWCL-1 NYXzcI9SSXCxcITvd4l{KEG|c3H5 NF:3[XUxNTFwNjFOwG0> NVTERXQ5OjRiaB?= MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEDQVFczPTh7M{K5NC=>
MM.1s MkO1RZBweHSxc3nzJGF{e2G7 MofzNE0yNjZizszN NHzJVJEzPCCq NIrTbmZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NIPNfFkzPTh7M{K5NC=>
HCT116 BAX BAK1 DKO M1nTNGZ2dmO2aX;uJGF{e2G7 NHrWTWs{NzFyIN88US=> MY[xNuKhcMLi M2\PbmROW09? NYmyUJpVcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u NYHscnhDOjV5MUWwNlg>
HCT116 MlH5SpVv[3Srb36gRZN{[Xl? Mn2zNVAh|ryP M3LPUlEzyqCqwrC= MkPiSG1UVw>? NW\jVYVCcW6lcnXhd4V{KEeIUD3MR|NDKHC3bnP0ZS=> NEHSSpQzPTdzNUCyPC=>
HCT116 MVLBeZRweGijZ4mgRZN{[Xl? M{L2XVExKM7:TR?= MUexNuKhcMLi MWnEUXNQ MULpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NGjPOpMzPTdzNUCyPC=>
HCT116 BAX BAK1 DKO NIHSeYxCfXSxcHjh[5khSXO|YYm= MVyxNEDPxE1? MW[xNuKhcMLi NEPudVZFVVOR MVfpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NVntNYQ3OjV5MUWwNlg>
U937 M3:zUGFxd3C2b4Ppd{BCe3OjeR?= M4jndFAvOTJ3LUKg{txO NFLYU5ozPCCq MXzlcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?= NWfZPZV6OjV5MUSwNlQ>
U937  NXPqT3ZPSXCxcITvd4l{KEG|c3H5 MVmwMlUh|ryP NI\TepEzPCCq MV3lcohidmOnczDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMh[XNid3XscEBieyCQb4jhJIxmfmWu NEX6ZokzPTdzNECyOC=>
HL-60 AAA-Bcl-2 Mny5RZBweHSxc3nzJGF{e2G7 MYCwMVUh|ryP NUW3PJpVPDhiaB?= MlG5TWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGHVO2MzPTdzMUS2NC=>
HL-60 EEE-Bcl-2 Mn;NRZBweHSxc3nzJGF{e2G7 Mm[1NE02KM7:TR?= NHG5dlU1QCCq M4jqUmlEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlLqNlU4OTF2NkC=
U87 NWDlOXpyTnWwY4Tpc44hSXO|YYm= Moq2OVAh|ryP NUjZc2V1OjRiaB?= MlTvdoVlfWOnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBOVVBvMjygUW1RNTF2IHHu[EBD[2xvMh?= NUPiOnN4OjV4Nke2OlM>
K562 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1foRVEuOTBizszN Mnm5OFghcA>? MXTEUXNQ M3rVN2lEPTB;Mk[uO{DPxE1? NU\VVokxOjV3OU[1OlE>
K562/Mcl -1-IRESBim MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HXXWlEPTB;OT6zJO69VQ>? M{XzflI2PTN3OUCw
K562/Bcl- 2-IRESBim Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDPT3lvUUN3ME2wMlM2KM7:TR?= Ml21NlU2OzV7MEC=
JurkatΔBak M4HrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7GcFl[UUN3ME61NEDPxE1? MV[yOVU{PTlyMB?=
HL60/VCR M1L4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRjFyMDFOwG0> M1j4OFI2PTN3OUCw
Kasumi-1 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfoZVNKSzVyPUCuNFEh|ryP NUPhSY9uOjV3M{W5NFA>
Kasumi-1/ABT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP1R4Y5UUN3ME2wMlUyKM7:TR?= M2rNV|I2PTN3OUCw
THP-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[wbVRKSzVyPUGuNlch|ryP MknsNlU2OzV7MEC=
C1498 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZwMUOg{txO NVfY[VhMOjV3M{W5NFA>
RPMI 8226 NEHJdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMkWg{txO M4j4b|I2PTN3OUCw
MM.1S MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwNECg{txO M1qzVFI2PTN3OUCw
NCI-H929 M33YUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm4[VNKSzVyPUG1MlIyKM7:TR?= M{XmUlI2PTN3OUCw
U266 NFnyN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe2cnNEUUN3ME2wMlY5KM7:TR?= Mm\3NlU2OzV7MEC=
MCF-7 NWniTnFXS2WubDDWbYFjcWyrdImgRZN{[Xl? MXi1JO69VQ>? MVm0PEBp M3frR2ROW09? MkPw[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>? M1u5NFI2PDB7MUK0
MCF-7 M1K2OGFxd3C2b4Ppd{BCe3OjeR?= MWm1JO69VQ>? MmPtOE8zPC92ODDo Mn;sSG1UVw>? MmPGbY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC= Mmi5NlU1ODlzMkS=
MCF-7 MnvDSpVv[3Srb36gRZN{[Xl? NFfvfWQ2KM7:TR?= M1fUcVI1KGh? MoW5SG1UVw>? NFrqR4tmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? MXuyOVQxQTF{NB?=
MDA-MB 231  MWDGeY5kfGmxbjDBd5NigQ>? M4XrclUh|ryP MWSyOEBp MUPEUXNQ NYfaRWp6\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi MmjPNlU1ODlzMkS=
ZR-75-1  NVrjTI05TnWwY4Tpc44hSXO|YYm= NILJXFM2KM7:TR?= M1jrR|I1KGh? M1;2N2ROW09? MXXlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> NGTBbY4zPTRyOUGyOC=>
A549 NH3Hd4JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4nGU|AuOjBizszN NGPoeYE4OiCq NFWzUVlFVVOR M3zPcoRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? M1vtZlI2Ozh6N{[y
H1299 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYewMVIxKM7:TR?= MlfIO|IhcA>? MWjEUXNQ MULk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv MnHqNlU{QDh5NkK=
HO-8910 Mn\6R4VtdCCYaXHibYxqfHliQYPzZZk> NWrmWJRTOC1{MDFOwG0> NWT1XG9ZPzJiaB?= MXHEUXNQ NET0O|dl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MYKyOVM5QDd4Mh?=
HT-29 NFXycFFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M17nS|AuOjBizszN M1OxZlczKGh? M2HoS2ROW09? NIizd3Vl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw M3jWSlI2Ozh6N{[y
HCT-116 M4\0RWNmdGxiVnnhZoltcXS7IFHzd4F6 MV6wMVIxKM7:TR?= NEPVO4U4OiCq M4\6Z2ROW09? M4fyR4Rm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NUDtdoJjOjV|OEi3OlI>
A549 NVfnXIhnSXCxcITvd4l{KEG|c3H5 NHTvelUzOCEQvF2= MX:0PEBp MkW1SG1UVw>? NWntV|EzcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG|cHnybY4> MnGxNlU{QDh5NkK=
H1299 NVjXUpJLSXCxcITvd4l{KEG|c3H5 MY[yNEDPxE1? MlfYOFghcA>? NIPZPW5FVVOR NWTDNnN6cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG|cHnybY4> M17wWVI2Ozh6N{[y
Sc-1 NUL2SY5{S2WubDDWbYFjcWyrdImgRZN{[Xl? NVLiZpdbOC5yMECxMVEh|ryP NULPVWE{QTZiaB?= MVjk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYSyOVM4OzVyOB?=
OcI-LY18 Ml\2R4VtdCCYaXHibYxqfHliQYPzZZk> MWSwMlAxODFvMTFOwG0> MmnqPVYhcA>? M1;qRoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3njS|I2Ozd|NUC4
RL  M4G3eWNmdGxiVnnhZoltcXS7IFHzd4F6 NYPnUItXOC5yMECxMVEh|ryP NWDQ[ndwQTZiaB?= MYrk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlnSNlU{PzN3MEi=
Caco-2 M{\pNWNmdGxiVnnhZoltcXS7IFHzd4F6 NWXrT45TOC1zMDFOwG0> M3LaOVI16oDLaNMg NUPNUlZJTE2VTx?= MUHJR|UxRTF7LkhihKnDvU1? M3jV[FI2OzB2M{iz
SW620 NHLPTYpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4HIUlAuOTBizszN MnzhNlTjiImqwrC= MWrEUXNQ MmizTWM2OD1zMj6yOQKBkcL3TR?= Mnr6NlU{ODR|OEO=
HaCaT NIi1e4NHfW6ldHnvckBCe3OjeR?= MYmxNQKBkc7:TR?= NHPnfVUzPC92ODDo NETTbVRFVVOR NHW2e21qdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= MmLhNlUzOTB5OUW=
A5-RT3 NEXM[2hHfW6ldHnvckBCe3OjeR?= MlTKNVDjiIoQvF2= NF\NW3ozPC92ODDo M{jXZmROW09? M{i2VYlv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= NVS4S3AxOjV{MUC3PVU>
A5-RT3 MX\GeY5kfGmxbjDBd5NigQ>? MofSOUDPxE1? Mni0OkBp NUXDOJN7TE2VTx?= NGqycpRqdmS3Y3XzJJRp\SC{ZXzlZZNmKG:oIH3peI9kcG:wZILpZYwheHKxdHXpcpMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDzeZJ3cX[jbDDpckBiKGOjc4Dhd4UucW6mZYDlcoRmdnRibXHucoVz MYiyOVIyODd7NR?=
U266 NIGwfHhHfW6ldHnvckBCe3OjeR?= MVW1NFAwPzVyIH7N NFzBNpczPC92ODDo NYLxTlA6TE2VTx?= MUXkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= M3XMVVI2OjB6OEi4
RPMI8226 MoPJSpVv[3Srb36gRZN{[Xl? MkHaOVAxNzd3MDDuUS=> M3LIdVI1NzR6IHi= Mmm3SG1UVw>? Mmq3[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt NYS1OYY{OjV{MEi4PFg>
MM.1S NYTPZ20yTnWwY4Tpc44hSXO|YYm= NV;yVm17PTByL{e1NEBvVQ>? NWe4T5NROjRxNEigbC=> NI\oeoVFVVOR Mnrm[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt M1W0[lI2OjB6OEi4
Clone A NHvweo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWwNE4z6oDVNkCg{txO MVy3NkBp MYHEUXNQ NWHiNGdbUUN3ME23MlUh|ryP MVuyOVIxQDh6Mh?=
CX-1 NEXz[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFroTm8xNjMkgKO2NEDPxE1? Mly3O|IhcA>? MkPsSG1UVw>? M3\ncWlEPTB;MT64JO69VQ>? NV3ue2JVOjV{MEi4PFI>
LS174T M2XMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofiNE4z6oDVNkCg{txO NWrPfJlHPzJiaB?= M3LjVWROW09? Mmn0TWM2OD1zOD6zJO69VQ>? M13kflI2OjB6OEiy
HT29 NX\Q[3lsSXCxcITvd4l{KEG|c3H5 NET6bG4yNzVxMUCg{txO MXu0PEBp M4jP[INifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnizNlUyQTJzOEi=
SW480 NEXiU|NCeG:ydH;zbZMhSXO|YYm= M1XqeVEwPS9zMDFOwG0> NFfqTnQ1QCCq M4XjbYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWCyOVE6OjF6OB?=
Colo205 NEnpb5dCeG:ydH;zbZMhSXO|YYm= NYnYTVlDOS93L{GwJO69VQ>? NWf4fI42PDhiaB?= M1[zO4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NInOWogzPTF7MkG4PC=>
Caco2 MXzBdI9xfG:|aYOgRZN{[Xl? M1\WSlEwPS9zMDFOwG0> Mnr2OFghcA>? M3Tz[4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3y2cVI2OTl{MUi4
UM-SCC22B MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPTO|IhcA>? NIfjUppFVVOR M2jWc2dKPTB;MUmgxtEhOi57IN88US=> MkCwNlUyOzl|OEe=
UM-SCC47 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:3NkBp NVzpd|lZTE2VTx?= MX7HTVUxRTF7INMxJFEzNjNizszN Mn\SNlUyOzl|OEe=
93-VU-147T NWHzUFVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr4O|IhcA>? MWjEUXNQ Mmm5S2k2OD12LkOgxtEhOy53IN88US=> NFLWUoUzPTF|OUO4Oy=>
UD-SCC2 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLRO|IhcA>? Mkm2SG1UVw>? NUm5[IlMT0l3ME2yPEDDuSB{Lkmg{txO MnT4NlUyOzl|OEe=
UPCI:SCC90 NYrzNVlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmWyO|IhcA>? Mlm5SG1UVw>? NFn3[4RIUTVyPU[uOkDDuSBzLkWg{txO NYfIcnZPOjVzM{mzPFc>
RPMI-8226  NHy2[FJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4LJOFEzPS9{NUCvOVAxKG6P NXHKb5dxPDiqwrC= Mn20SG1UVw>? MlfZ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NG\DWFYzPTByOEKwNi=>
OPM-2  MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVq1cVRYOTJ3L{K1NE82ODBibl2= NWXMVYY3PDiqwrC= NF3KbYlFVVOR NYPuNoNU\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Ml7SNlUxODh{MEK=
RPMI-8226  M2XwVWFxd3C2b4Ppd{BCe3OjeR?= MXqxNlUwOjVyL{WwNEBvVQ>? MYG0PIjDqA>? MVHEUXNQ NXy4OlBscW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3nGOlI2ODB6MkCy
OPM-2  MVnBdI9xfG:|aYOgRZN{[Xl? NGrrOZAyOjVxMkWwM|UxOCCwTR?= NHLvd5U1QGkEoB?= M1rEfGROW09? MoLGbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3nZNFI2ODB6MkCy
COG-LL-319 MnXzSpVv[3Srb36gRZN{[Xl? NIewTWgyODBibl2= M4nDc|EwOy94IHi= MWnEUXNQ MXzpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm MknTNlQ6PTF2N{K=
RS4;11 MlPUSpVv[3Srb36gRZN{[Xl? MYOxNFAhdk1? M4W5eFEwOy94IHi= MVLEUXNQ Mk\CbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? M2XiVlI1QTVzNEey

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]


Kinase Assay:


+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:


+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% Propylene glycol, 5% Tween 80, 65% D5W

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43


CAS No. 852808-04-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Related Antibodies

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID